Louisiana State Employees Retirement System Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Louisiana State Employees Retirement System raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,500 shares of the specialty pharmaceutical company’s stock after buying an additional 100 shares during the period. Louisiana State Employees Retirement System’s holdings in Supernus Pharmaceuticals were worth $884,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. State of Alaska Department of Revenue raised its position in Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares during the last quarter. Texas Permanent School Fund raised its position in shares of Supernus Pharmaceuticals by 0.5% in the first quarter. Texas Permanent School Fund now owns 36,288 shares of the specialty pharmaceutical company’s stock worth $1,136,000 after buying an additional 178 shares in the last quarter. Suntrust Banks Inc. raised its position in shares of Supernus Pharmaceuticals by 1.8% in the first quarter. Suntrust Banks Inc. now owns 19,913 shares of the specialty pharmaceutical company’s stock worth $622,000 after buying an additional 343 shares in the last quarter. Juncture Wealth Strategies LLC raised its position in shares of Supernus Pharmaceuticals by 0.8% in the first quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after buying an additional 433 shares in the last quarter. Finally, Arizona State Retirement System raised its position in shares of Supernus Pharmaceuticals by 2.4% in the first quarter. Arizona State Retirement System now owns 26,101 shares of the specialty pharmaceutical company’s stock worth $817,000 after buying an additional 600 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (SUPN) traded down 0.69% during mid-day trading on Friday, hitting $43.20. 626,131 shares of the stock were exchanged. The company’s 50-day moving average is $42.56 and its 200-day moving average is $34.77. Supernus Pharmaceuticals, Inc. has a 1-year low of $17.25 and a 1-year high of $46.45. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of 21.80 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The company had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $68.54 million. Equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Louisiana State Employees Retirement System Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.com-unik.info/2017/08/19/louisiana-state-employees-retirement-system-acquires-100-shares-of-supernus-pharmaceuticals-inc-nasdaqsupn-updated-updated.html.

A number of equities analysts have commented on the stock. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Piper Jaffray Companies reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Cowen and Company reiterated a “positive” rating and issued a $50.00 price objective (up previously from $40.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 3rd. Finally, Janney Montgomery Scott started coverage on shares of Supernus Pharmaceuticals in a report on Friday, July 14th. They issued a “neutral” rating and a $47.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $48.43.

In other news, VP Padmanabh P. Bhatt sold 5,500 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $34.90, for a total transaction of $191,950.00. Following the completion of the sale, the vice president now owns 43,887 shares in the company, valued at approximately $1,531,656.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 2,500 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the sale, the vice president now owns 37,500 shares of the company’s stock, valued at approximately $1,346,250. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,000 shares of company stock valued at $1,130,524. 6.70% of the stock is owned by corporate insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit